Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WHR1 | P49842 | 6/20 | 0.44 |
| ▸ | GAK | O14976 | 1/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.35 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23623106 | 0.85 | ENPP1 (0.40) | GAKALKGCKMAP3K12OPRK1 | |
| SCHEMBL13027673 | 0.83 | NOS1 (0.43) | GAKGCKOPRK1ENPP1 | |
| SCHEMBL22803865 | 0.81 | TRPV1 (0.42) | SCN10AFFAR2PIK3CAMTORPDE10A | |
| SCHEMBL20918773 | 0.81 | ACHE (0.50) | ALK | |
| SCHEMBL30412557 | 0.81 | TRPV1 (0.42) | SCN10AFFAR2PIK3CAMTORPDE10A | |
| SCHEMBL26499822 | 0.81 | MAP3K12 (0.35) | GAKALKGCKMAP3K12OPRK1 | |
| SCHEMBL15652664 | 0.79 | PDE10A (0.51) | GAKPIK3CAMTORPDE10A | |
| SCHEMBL23623071 | 0.79 | PIK3CA (0.37) | SCN10AFFAR2PIK3CAMTOR | |
| SCHEMBL23166934 | 0.78 | SMN1; SMN2 (0.42) | SCN10AGCKPIK3CAMTOR | |
| SCHEMBL23612034 | 0.77 | PIK3CA (0.44) | SCN10AFFAR2PIK3CAMTOROPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| WO-2021138419-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC, (US) | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | WHR1 535/4885GAK 1513/4885SCN10A 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.